This is inhaled, don’t forget they talk about subcutaneous, from a medical and regulatory perspective, a completely different animal, no issues or change here, except maybe the need for sng just got a lot stronger
Other forms are not standing up well, the interferon reference included in the list which did not work was subcutaneous mode, and also, not in a combination therapy , from my reading of the non peer review WHO draft paper
Numis changes everything, I blocked and filtered anyone In recent weeks with unsubstantiated wild upper prices for syn, and have been enjoying a relatively ramp and agenda free updates on what is essentially an excellent company and science and potential future case study. Honestly would not have thought of £9+, but the £50 (best case bullish, mind) valuation makes me want much more reward for this fantastic company and its supporters, than single digit share estimates now.
Got to be careful to read what’s in the RNS, not what we want it to say, in general, but in this case, wow! Positive, positive and positive, there is no other way to interpret this. Well done team Blautix!
Numis is an ambitious, dynamic and innovative investment bank, driven to excel across all aspects of its delivery. We place long-term partnership at the very heart of our mission and strive to become the investment bank of a generation.
We are proud to have the largest client base by number of corporates in the UK, and through combining our leading component services such as M&A solutions, equity sales and trading and debt advisory, we operate at the very forefront of the industry with specialist expertise in the UK market.
Thanks gmcc, I found a lot (really a lot of others), but many similar studies have been hospital or university based in Japan, so some major sifting needed To get the commercial affiliates or funding partners. If I get the chance again, I will sit down with a fine tooth comb and magnifying glass. Something to do while watching this unnatural horizontal saw tooth pattern in the intradays!
a very good update in my view also. more secure cash position, pipeline sales activities and seems more positive news on the way. I didn't see much evidence of downplaying anything or talking around elephants in the room, even the US deal, not landed yet, was mentioned in a positive light, so short term seems very encouraging for q3-4.
New to the board, so this may have been covered in the past re 301, but this article dated June ish this year, shows the top 10 pharma in Japan, with a little dossier of their specialities. I cannot cross reference enough about 301 to eliminate candidates to narrow this list down with confidence (for example, is it ok to remove true western pharma from the list, if so then there are 6 Japanese companies remains, or....maybe Val were approached by a smaller firm, not in the top 10, but that doesn’t seem likely) and maybe the narrow down task would be fruitless, but this may help someone with a keen eye, and better skills than me to share an insight, and it may be satisfying to know that the partner could be in this list!
I don't normally look this closely at intraday data, but today I had a chance today, to me also, seems clear, testing of prices. I don't know if that qualifies as games, but it could cause panic in some, watching it live in the moment.
(ST I’m Still learning here, sorry if a basic question). Last director deal poster was 7th August, so does that mean, if something was ‘imminent’ so to speak, with the inside knowledge you mention, it couldn’t happen until at least a month had passed?
RE: Negotiated trades - in guessing lol14 Sep 2020 08:02
Agree, big change was contingent upon real news. The tweet did contain and make inferences to public domain knowledge. Nothing really changes, but the Friday FOMO bunch could move into others, potentially based on the other AIM RNSs that came out this morning. Emotion, Drop, stagger, then gently rise back, seems like a typical AIM day so far.
New to this site and forum, and still working out how things work, so apologies if there is an alternative place for this question.
In my research Im trying to establish fact, and filter out the ramping and deramping comments from other excellent inputs on the board. I spotted this recent news article from the bbc saying tests that give a yes/ no may also falsely indicate the presence of long gone, but dead virus fragments : https://www.bbc.co.uk/news/health-54000629
Subsequent press announcements, relating to a drop in sales due to delays in FDA clearance also emerge. Not sure if that is related based on what I read, but on the technical topic of the tests, does anyone with a more scientific background and understanding think that GDR test may be subject to the limitations highlighted in the bbc news article? If so, how easily would it be for their software to provide a baseline, or also indicate the number of PCR cycles, to alleviate this, if it is an issue?